Extrait

Omalizumab will be given as add-on treatment to optimized asthma therapy in patients with severe persistent asthma, who demonstrate inadequate asthma symptom control. Response to omalizumab over time will be assessed by physicians and patients evaluating the overall improvement in control of their asthma. THIS STUDY IS NOT ENROLLING PATIENTS IN THE US.

Critère d'inclusion

• Asthma

Pays

• Belgium
• Canada
• Denmark
• Germany
• Greece
• Hungary
• Ireland
• Israel
• Italy
• Norway
• Poland
• Portugal
• Spain
• Sweden
• Switzerland
• Turkey
• United Kingdom

Liens

• ictrp
• nct